Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

May 30, 2022

Study Completion Date

December 22, 2022

Conditions
Plasmodium Falciparum Malaria
Interventions
OTHER

GA2

15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.

OTHER

GA1

10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.

OTHER

Placebo

5 volunteers will receive 50 uninfected mosquito bites.

Trial Locations (1)

2333 ZA

Leiden University Medical Center, Leiden

All Listed Sponsors
lead

Leiden University Medical Center

OTHER

NCT04577066 - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. | Biotech Hunter | Biotech Hunter